🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. OPDIVO 10 mg/mL concentrate for solution for infusion., FLUOROURACIL , Oxaliplatino Sandoz, LEDERFOLIN 175 mg polvere per soluzione per infusione, FLUOROURACIL , SIMVASTATIN, CAPECITABINE

    Fondazione Telethon ETS

    advanced or metastatic gastrooesophageal carcinoma HER2 negative and ARID1A mutated

    phase 2 small molecule active

    1 trial

  2. OPDIVO 10 mg/mL concentrate for solution for infusion., Inrebic 100 mg hard capsules

    The George Institute

    Primary and secondary Myelofibrosis

    phase 2 small molecule active

    1 trial

  3. OPDIVO 10 mg/mL concentrate for solution for infusion., Regorafenib_IJB

    The George Institute

    Locally-advanced stage II-III rectal cancer

    phase 2 small molecule active

    1 trial

  4. OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab intravenous

    The George Institute

    Adult participants with advanced unresectable or metastatic soft-tissue sarcoma.

    phase 2 small molecule active

    1 trial

  5. OPDIVO 10 mg/mL concentrate for solution for infusion., Stivarga 40 mg film-coated tablets, anti-CTLA-4 NF Probody® mAb

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC)).

    phase 2 small molecule active

    1 trial

  6. OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion

    Ningbo Cancer Hospital

    NEOREM: Localized solid malignancies that are eligible to receive neo-adjuvant therapy and have medical unmet needs related to disease-free survival, overall survival or quality of life / NEO-1: Resectable stage III cutaneous or mucosal melanoma amenable to intratumoral neo-adjuvant immunotherapy.

    phase 2 small molecule active

    1 trial

  7. ORSERDU 86 mg film-coated tablets, ABEMACICLIB, ABEMACICLIB, ORSERDU 345 mg film-coated tablets, ABEMACICLIB

    Stemline Therapeutics B.V.

    Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  8. OXALIPLATIN, AFLIBERCEPT, PANITUMUMAB, BEVACIZUMAB, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, IRINOTECAN, FLUOROURACIL, CETUXIMAB, AVELUMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY

    phase 2 small molecule active

    1 trial

  9. OXALIPLATIN, AZD0901, CAPECITABINE, FLUOROURACIL, AZD7789, volrustomig, CAPECITABINE, CALCIUM FOLINATE, Rilvegostomig

    AstraZeneca AB

    Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  10. OXALIPLATIN, CALCIUM FOLINATE, Quemliclustat, Zimberelimab, FLUOROURACIL, DOMVANALIMAB

    Arcus Biosciences

    Upper Gastrointestinal Tract Cancer, Advanced Upper Gastrointestinal Tract Malignancies, Gastrointestinal Tract Malignancies

    phase 2 small molecule active

    1 trial

  11. OXALIPLATIN, CISPLATIN, OXALIPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., PEMBROLIZUMAB, CAPECITABINE, TRASTUZUMAB, OXALIPLATIN, Rilvegostomig, CAPECITABINE, FLUOROURACIL, volrustomig, DS-8201a

    AstraZeneca AB

    Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressing gastric, GEJ and esophageal cancer

    phase 2 small molecule active

    1 trial

  12. OXALIPLATIN, ETOPOSIDE, CISPLATIN, CALCIUM FOLINATE, CAPECITABINE, IRINOTECAN, PACLITAXEL, FLUOROURACIL, TRABECTEDIN, DOCETAXEL, IFOSFAMIDE, PACLITAXEL ALBUMIN-BOUND, DOXORUBICIN, MITOTANE, CARBOPLATIN, GEMCITABINE

    Ningbo Cancer Hospital

    Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanced or metastatic cancer

    phase 2 small molecule active

    1 trial

  13. OXALIPLATIN, PANITUMUMAB, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, BEVACIZUMAB, NIVOLUMAB, TRASTUZUMAB

    Ningbo Cancer Hospital

    Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower esophagus, gastroesophageal junction and gastric) and with known dihydropyrimidine dehydrogenase (DPD) deficiency defined as plasma uracil concentration ≥16 ng/ml, who undergo first-line treatment

    phase 2 small molecule active

    1 trial

  14. Obatoclax

    Teva Pharma GmbH

    Extensive-stage Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  15. Obecabtagene Autoleucel

    Autolus GmbH

    Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  16. Obecabtagene autoleucel

    Autolus GmbH

    Acute Lymphocytic Leukemia (ALL)

    phase 2 small molecule active

    1 trial

  17. Obecabtagene autoleucel

    Autolus GmbH

    Lupus Nephritis

    phase 2 mab active

    1 trial

  18. Obinutuzumab

    The First People's Hospital of Lianyungang

    Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  19. Odronextamab

    Regeneron UK Limited

    B-cell Non-Hodgkin Lymphoma (B-NHL)

    phase 2 small molecule active

    2 trials

  20. Odronextamab

    Regeneron UK Limited

    Recurrent Diffuse Large B-Cell Lymphoma

    phase 2 mab active

    1 trial

  21. Odronextamab

    Regeneron UK Limited

    Follicular Lymphoma

    phase 2 mab active

    1 trial

  22. Ofev 100 mg soft capsules, Ofev 150 mg soft capsules

    Pari Pharma GmbH

    Adult patients aged 18 and over with unicentric hyalino-vascular Castleman's disease

    phase 2 small molecule active

    1 trial

  23. Ogivri 150 mg powder for concentrate for solution for infusion, TUKYSA 50 mg film-coated tablets, TUKYSA 150 mg film-coated tablets

    The George Institute

    HER3-mutant and HER2-not amplified metastatic breast cancer

    phase 2 small molecule active

    1 trial

  24. Olaparib, ETOPOSIDE TEVA 20 mg/ml, concentrato per soluzione per infusione, Cisplatino Sandoz 1 mg/ml – Concentrato per soluzione per infusione, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, CARBOPLATINO TEVA 10 mg/ml

    Istituto Gentili S.r.l.

    Extensive-Stage Small-Cell Lung Cancer (ES SCLC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources